Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Published Date: 31 Dec 2024

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

2.

New research uncovers link between cancer pathway and blood-retina barrier function

3.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

4.

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

5.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot